| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/28/2005 | CA2542504A1 Lipids containing omega-3 and omega-6 fatty acids |
| 04/28/2005 | CA2542337A1 Cancer gene therapeutic drug |
| 04/28/2005 | CA2542335A1 Cancer gene therapeutic drug |
| 04/28/2005 | CA2542290A1 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof |
| 04/28/2005 | CA2542128A1 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| 04/28/2005 | CA2542113A1 Compositions useful as inhibitors of protein kinases |
| 04/28/2005 | CA2541425A1 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| 04/28/2005 | CA2541405A1 The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin |
| 04/28/2005 | CA2541264A1 Breast cancer treatment regimen |
| 04/28/2005 | CA2539767A1 1,3-benzoxazolyl derivatives as kinase inhibitors |
| 04/28/2005 | CA2526691A1 High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens |
| 04/27/2005 | EP1526183A2 Dimer of a peptide derived from the C-terminal sequence of human superoxide dismutase facilitating the penetration of a substance into cells and/or cell nuclei |
| 04/27/2005 | EP1526133A1 Epothilone derivatives |
| 04/27/2005 | EP1526132A2 Substituted oxazolidinone derivatives and their use as factor xa inhibitors |
| 04/27/2005 | EP1525889A1 Liquid pharmaceutical composition containing an erythropoietin derivative |
| 04/27/2005 | EP1525887A1 Drugs including anticancer agents and immunopotentiators and health foods and drinks |
| 04/27/2005 | EP1525883A1 Ciclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/27/2005 | EP1525310A2 Cancer therapy by modulating cdc42-activity |
| 04/27/2005 | EP1525308A2 Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| 04/27/2005 | EP1525306A1 Three-dimensional structure of dipeptidyl peptidase iv |
| 04/27/2005 | EP1525223A2 Ox40 (=cd134) receptor agonists and therapeutic use |
| 04/27/2005 | EP1525215A1 Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy |
| 04/27/2005 | EP1525208A2 Novel difluorinated gem compounds, preparation methods thereof and applications of same |
| 04/27/2005 | EP1525205A2 Novel substituted pyrazolo( 1,5-a /i ]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same |
| 04/27/2005 | EP1525201A1 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| 04/27/2005 | EP1525200A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 04/27/2005 | EP1525199A1 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 04/27/2005 | EP1525198A2 Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof |
| 04/27/2005 | EP1525001A1 Conjugates of porphyrin compounds with chemotherapeutic agents |
| 04/27/2005 | EP1525000A2 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 04/27/2005 | EP1524998A1 Stable pharmaceutical composition comprising erythropoietin |
| 04/27/2005 | EP1524997A1 Stable liquid parenteral parecoxib formulation |
| 04/27/2005 | EP1524995A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 04/27/2005 | EP1524986A1 Metal cluster nano-compounds for treating tumor diseases |
| 04/27/2005 | EP1524973A1 A pharmaceutical composition useful for treating chronic myeloid leukemia |
| 04/27/2005 | EP1427430B1 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary system caused by sex hormones |
| 04/27/2005 | EP1423739A4 Source wavelength shifting apparatus and method for delivery of one or more selected emission wavelengths |
| 04/27/2005 | EP1423110A4 Cbi analogues of cc-1065 and the duocarmycins |
| 04/27/2005 | EP1419150B1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 04/27/2005 | EP1374873B1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy |
| 04/27/2005 | EP1358320A4 68730 and 69112 protein kinase molecules and uses therefor |
| 04/27/2005 | EP1150707B1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS |
| 04/27/2005 | EP1135153B1 Uses for eph receptor antagonists and agonists to treat vascular disorders |
| 04/27/2005 | EP1121153B1 Site-specific labeling of disulfide-containing targeting vectors |
| 04/27/2005 | EP1040098B1 Integrin receptor antagonists |
| 04/27/2005 | EP0931077B1 Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase |
| 04/27/2005 | EP0838453B1 Heterocyclic carboxylic acid derivatives and drugs containing the same |
| 04/27/2005 | CN1610751A Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof |
| 04/27/2005 | CN1610748A Recombinant MVA capable of expressing structural HCV antigens |
| 04/27/2005 | CN1610743A Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 04/27/2005 | CN1610696A Antibodies that immunospecifically bind to TRAIL receptors |
| 04/27/2005 | CN1610695A Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| 04/27/2005 | CN1610694A Formulation of lymphokines and method of use thereof for local or bath local and systemic control of proliferative cell disorders |
| 04/27/2005 | CN1610691A 2-O-(beta-D-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 04/27/2005 | CN1610681A Polycyclic compounds having anti-tumor activity |
| 04/27/2005 | CN1610675A Benzothiazole- and benzoxazole-4, 7-dione derivatives and their use as CDC25 phosphatase inhibitors |
| 04/27/2005 | CN1610674A Use of 2-amino-thiazoline derivatives as inhibitors of inducible NO-synthase |
| 04/27/2005 | CN1610669A Heteroaryl-substituted aminocyclohexane derivatives |
| 04/27/2005 | CN1610659A Carboxylic acid derivative |
| 04/27/2005 | CN1610549A Epermycin derivative for treating difficult to cure tumor |
| 04/27/2005 | CN1610545A Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor |
| 04/27/2005 | CN1610543A Use of N, N-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy |
| 04/27/2005 | CN1609206A Crystal structure of oxidosqualene cyclase |
| 04/27/2005 | CN1609203A Human ovary carcinoma resisting monoclonal antibody hybridoma cell line and its monoclonal antibody and application |
| 04/27/2005 | CN1609124A Calreticulin-tumor necrosis factor correlated apoptosis inducing ligand fusion protein and its prepn and use |
| 04/27/2005 | CN1609118A Cell wall acyl-alanyl-D-isoglutamine derivative and its prepn, medicine composition and use |
| 04/27/2005 | CN1608676A Orally taken carrier to transduce liver and intestine cell |
| 04/27/2005 | CN1608663A Antitumor medicine and its production process |
| 04/27/2005 | CN1608653A Tranquilizing medicine powder for treating hepatic coma |
| 04/27/2005 | CN1608643A Recipe of Chinese herbal medicine for treating leucopenia |
| 04/27/2005 | CN1608637A Prepn process of medicine for treating malignant tumor |
| 04/27/2005 | CN1608636A Prepn process of one kind of medicine |
| 04/27/2005 | CN1608616A Application of coniferyl ferulate in anticancer medicine |
| 04/27/2005 | CN1198834C Water soluble produgs of hindered alcohols or phenols |
| 04/27/2005 | CN1198818C Compound with growth hormone releasing properties |
| 04/27/2005 | CN1198816C Farnesyl protein transferase inhibitors |
| 04/27/2005 | CN1198804C Amide compounds and use thereof |
| 04/27/2005 | CN1198802C Chalcones having antiproliferactive activity |
| 04/27/2005 | CN1198645C Anticancer capsule containing bioactive enzyme extracted from venom and its prepn |
| 04/27/2005 | CN1198639C Immune enhancing compositions |
| 04/27/2005 | CN1198633C Chinese medicine for treating cancer and preparation thereof |
| 04/27/2005 | CN1198616C Oral formulations for anti-tumor compounds |
| 04/27/2005 | CN1198609C Use of taxiol stabilized by albumin in preparing medicine for treating body tumor and medicine obtained therefrom |
| 04/27/2005 | CN1198590C Antibody and polyalkylene glycol-bonded liposome |
| 04/27/2005 | CN1198589C Method for controlling liposome size |
| 04/26/2005 | US6884907 Containing carboxylic acid groups; diagnosis; prophylaxis |
| 04/26/2005 | US6884869 Pentapeptide compounds and uses related thereto |
| 04/26/2005 | US6884808 Acids and salts such as 4-(4-(2-(2-(5,6,7,8-Tetrahydro-5,5,8, 8-tetramethylquinoxalyl))pyrrolyl))benzoic acid, used retinoic acid receptor agonists for the prophylaxis of cancer, skin disorders, asthma, alopecia or autoimmune diseases |
| 04/26/2005 | US6884804 Inhibitors of Src and other protein kinases |
| 04/26/2005 | US6884800 Nitrogen compounds such as 10-Chloro-3-imidazol-1-yl-2,3-dihydro-1H-pyrido(3,2,1-kl)phenothiazine, used for prophylaxis of respiratory system and skin disorders, autoimune diseases, tumors or atherosclerosis and AIDS |
| 04/26/2005 | US6884799 Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof |
| 04/26/2005 | US6884795 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol |
| 04/26/2005 | US6884786 Antitumoral composition based on immunogenic polypeptide with modified cell location |
| 04/26/2005 | US6884595 Test tumor cell modulation; analyzing chromosomes |
| 04/26/2005 | US6884574 Methods of identifying agents which inhibit GPR-9-6 |
| 04/26/2005 | US6884440 Sodium metasilicate, borax,sodium thiosulfate, potassium carbonate, refined cane sugar and water; improvement in disease resistance, weight gain rate, crop yield, crop quality, and harvest time |
| 04/26/2005 | US6884439 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 04/26/2005 | CA2053253C New aryl-and heteroarylethenylene derivatives and process for their preparation |
| 04/21/2005 | WO2005035762A1 Cytokine involved in epithelial-mesenchymal transition |
| 04/21/2005 | WO2005035754A1 Double specific antibodies substituting for functional protein |